The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
Open Access
- 1 June 1994
- journal article
- case report
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 269 (22) , 15419-15422
- https://doi.org/10.1016/s0021-9258(17)40694-6
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in HumansBiochemistry, 1994
- Stereoselective disposition of hexobarbital and its metabolitesPharmacogenetics, 1994
- Gene Structure and Upstream Regulatory Regions of Human CYP2C9 and CYP2C18Biochemical and Biophysical Research Communications, 1993
- Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation PolymorphismsTherapeutic Drug Monitoring, 1993
- Metabolic polymorphismsPharmacology & Therapeutics, 1993
- Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjectsPharmacogenetics, 1992
- Biochemical Mechanisms of Constitutive and Regulated Pre-mRNA SplicingAnnual Review of Cell Biology, 1991
- Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamilyBiochemistry, 1991
- Genetic polymorphism of S-mephenytoin hydroxylationPharmacology & Therapeutics, 1989
- Amitriptyline Pharmacokinetics and Clinical Response: II. Metabolic Polymorphism Assessed by Hydroxylation of Debrisoquine and MephenytoinInternational Clinical Psychopharmacology, 1986